

# GENLINK PHARMA SOLUTIONS PRIVATE LIMITED

(Formerly known as GENLINK PHARMA INVESTMENTS PRIVATE LIMITED)

Date: 30/09/2019

To  
The Manager  
Listing Department  
BSE Limited  
Bombay Stock Exchange,  
P. J. Towers, Dalal Street,  
Mumbai-400001.

Ref: Scrip code 956084 and ISIN INE988W07019

Subject: Submission under Regulation 52(1), 52(3), 52(4) and 52(5) of Securities and Exchange Board of India (Listing Obligation and Disclosure requirements) Regulations, 2015.

Dear Sir/Madam,

With reference to the subject matter, please find enclosed the following:

- i. The annual financial results of the Company for the financial year ended 31<sup>st</sup> March, 2019 along with the Annual Audit Report issued by the Statutory Auditors pursuant to Regulation 52(1) of SEBI (LODR), 2015.
- ii. The disclosure of the items as required under Regulation 52(4) of SEBI (LODR), 2015 (Annexure 1).
- iii. A certificate signed by debenture trustee pursuant to Regulation 52(5) of SEBI (LODR), 2015 (Annexure 2).
- iv. Declaration by Mr. Ganesh Prasad Gupta, Compliance Officer pursuant to Regulation 52(3)(a) of the SEBI (LODR), 2015.
- v. Statement of material deviation Regulation 52(7) of SEBI (LODR), 2015.

Please take the above information on your records.

For Genlink Pharma Solutions Private Limited

  
G.A Gupta  
Company Secretary and  
Compliance Officer  
Membership no. ACS33925



**Shankarlal Jain & Associates LLP**  
**Chartered Accountants**



12, Engineer Building, 265 Princess Street, Mumbai - 400 002. India E-mail : info@sljainindia.com

Tel : +91 22 2203 6623, 2206 5739 Fax : +91 22 2208 6269 Website : www.sljainindia.com

To,  
The Board of Directors,  
M/S GENLINK PHARMA SOLUTIONS PRIVATE LIMITED,  
(Formerly known as GENLINK PHARMA INVESTMENTS PRIVATE LIMITED)  
Mumbai

Dear Sir,

**Re: Auditor's Report on Yearly Financial Results as on 31st March 2019 of M/s. GENLINK PHARMA SOLUTIONS PRIVATE LIMITED, (Formerly known as GENLINK PHARMA INVESTMENTS PRIVATE LIMITED) pursuant to the Regulation 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015.**

**Introduction**

We have audited the Yearly Financial results of M/s. GENLINK PHARMA SOLUTIONS PRIVATE LIMITED, (Formerly known as GENLINK PHARMA INVESTMENTS PRIVATE LIMITED) for the year to date results for the period 1<sup>st</sup> April 2018 to 31<sup>st</sup> March 2019, attached herewith, being submitted by the Company pursuant to the requirement of Regulation 52 of the of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015. These Yearly financial results have been prepared on the basis of the interim financial statements, which are the responsibility of the Company's Management and have been approved by the Board of Directors. Our responsibility is to express an opinion on these financial statements based on our audit of such interim financial statements, which have been prepared in accordance with the recognition and measurement principles laid down in Accounting Standard for Interim financial Reporting (AS 25/ Ind AS 34), prescribed, under section 133 of the Companies Act, 2013 read with relevant rules issued there under; or by the Institute of Chartered Accountants of India, as applicable and other accounting principles generally accepted in India.

**Scope of Review**

We conducted our audit in accordance with the Auditing Standards accepted in India. Those standards require that we plan and perform the audit to obtain reasonable assurance as to whether the financial statements are free of material misstatement(s). An audit includes examining, on test basis, evidence supporting the amounts disclosed as financial result. An audit also includes assessing the accounting principles used and significant estimates made by management. We believe that our audit provides reasonable basis for our opinion.



**Shankarlal Jain & Associates LLP**  
**Chartered Accountants**



12, Engineer Building, 265 Princess Street, Mumbai - 400 002. India E-mail : info@sljainindia.com

Tel : +91 22 2203 6623, 2206 5739 Fax : +91 22 2208 6269 Website : www.sljainindia.com

**Conclusion**

In our opinion and to the best of our information and according to the explanations given to us these Yearly financial results to date results;

i) are presented in accordance with the requirements of Regulation 52 of the SEBI (Listing Obligations and Disclosure Requirement) Regulations, 2015 in this regard; and

ii) give a true and fair view of the net profit and other financial information for the year to date results for the period from 1<sup>st</sup> April 2018 to 31<sup>st</sup> March 2019.

For SHANKARLAL JAIN & ASSOCIATES LLP,  
CHARTERED ACCOUNTANTS

FIRM REG.NO:109901W/ W100082

SATISH JAIN  
PARTNER

MEMBERSHIP NO. 48874  
UDIN: 19048874AAAAFA3412

PLACE: MUMBAI  
DATE: 30/09/2019



# GENLINK PHARMA SOLUTIONS PRIVATE LIMITED

(Formerly Genlink Pharma Investments Private Limited)

CIN No : U74110MH2016PTC280765

Regd Off. Office No - 1704, 17th Floor, Kesar Solitaire, Plot No. 5, Sector 19, Sanpada Navi Mumbai, 400705, Maharashtra, India.


## Statement of Standalone Assets & Liabilities as on 31st March, 2019

INR

Sr. No.	PARTICULARS	As On 31-Mar-19 Audited	As On 31-Mar-18 Audited
	<b>ASSETS</b>		
	<b>Property, plant and Equipment</b>		
1	Property	3,04,33,702	-
2	Intangible Assets	-	-
3	Financial assets (others)	-	-
4	Non current tax assets (Net)	-	-
5	Other Non current assets	24,89,95,479	24,89,95,479
	<b>Total Non-current assets</b>	<b>27,94,29,181</b>	<b>24,89,95,479</b>
	<b>Current Assets</b>		
1	Financial assets	-	-
2	Investments	-	-
3	Trade and other receivables	14,40,400	-
4	Cash and cash equivalents	6,601	23,387
5	Other financial assets	-	-
6	Other current assets	34,168	45,198
	<b>Total Current assets</b>	<b>14,81,169</b>	<b>68,585</b>
	<b>TOTAL ASSETS</b>	<b>28,09,10,350</b>	<b>24,90,64,064</b>
	<b>EQUITY AND LIABILITIES</b>		
	<b>Equity</b>		
1	Equity Share Capital	1,00,000	1,00,000
2	Other Equity	21,27,852	(27,69,928)
	<b>Total Equity</b>	<b>22,27,852</b>	<b>(26,69,928)</b>
	<b>Non-current Liabilities</b>		
1	Financial liabilities		
	(a) Long-term borrowings	27,29,48,634	25,01,50,000
	(b) Other Financial Liabilities	-	-
2	Long term Provision	-	-
3	Deferred Tax Liabilities (net)	-	-
4	Other Non-current Liabilities	-	-
	<b>Total Non-current Liabilities</b>	<b>27,29,48,634</b>	<b>25,01,50,000</b>
	<b>Current Liabilities</b>		
1	Financial Liabilities		
	(a) Trade and Other payables	-	-
	(b) Other financial liabilities	-	-
2	Short term provisions	5,78,000	50,000
3	Other current liabilities	51,55,864	15,33,992
	<b>Total Current Liabilities</b>	<b>57,33,864</b>	<b>15,83,992</b>
	<b>TOTAL EQUITY AND LIABILITIES</b>	<b>28,09,10,350</b>	<b>24,90,64,064</b>
		0.00	0.00

For Genlink Pharma Solutions Private Limited

Susheel Koul  
Managing Director  
DIN: 00925887



Date: 30th September 2019  
Place: Navi Mumbai

\*

# GENLINK PHARMA SOLUTIONS PRIVATE LIMITED

(Formerly Genlink Pharma Investments Private Limited)

CIN No : U74110MH2016PTC280765

Regd Off. Office No - 1704, 17th Floor, Kesar Solitaire, Plot No. 5, Sector 19, Sanpada Navi Mumbai, 400705, Maharashtra, India.

## Standalone unaudited Financial Results for the Half and Year ended 31st March 2019

INR

Sr. No.	Particulars	Year to date ended	Previous Year Ended
		31-Mar-19	31-Mar-18
		Audited	Audited
1	Income from Operations		
(i)	Net Sales/Income from Operations (Net of excise duty)	78,70,000	-
(ii)	Other Income	-	-
	<b>Total Income from Operations</b>	<b>78,70,000</b>	<b>-</b>
2	Expenses		
(i)	Cost of Material Consumed	-	-
(ii)	Purchase of Stock in trade	-	-
(iii)	Change in Inventory of Finished Goods, Work In progress and Stock in trade	-	-
(iv)	Employee Benefits Expenses	-	-
(v)	Depreciation and Amortization Expenses	2,54,306	-
(vi)	Finance Cost	7,97,338	18,539
(vii)	Other Expenses	7,00,055	5,05,728
	<b>Total Expenses</b>	<b>17,51,699</b>	<b>5,24,267</b>
3	<b>Profit/(Loss) from operation before tax</b>	<b>61,18,301</b>	<b>(5,24,267)</b>
4	Tax Expenses	12,20,521	30,680
5	<b>Profit/(Loss) from ordinary activities for the period</b>	<b>48,97,780</b>	<b>(5,54,947)</b>
6	Other Comprehensive Income		
(i)	Items that will not be reclassified to profit or loss	-	-
(ii)	Items that will be reclassified to profit or loss	-	-
	<b>Total Comprehensive Income/(Loss) for the period</b>	<b>48,97,780</b>	<b>(5,54,947)</b>
7	<b>Paid up Equity Share Capital of 10/- each</b>	<b>1,00,000</b>	<b>1,00,000</b>
8	<b>Earning per Share(not annualised)</b>		
	Basic	489.78	-55.49
	Diluted	489.78	-55.49

For Genlink Pharma Solutions Private Limited

Susheel Koul

Managing Director

DIN: 00925887



Date: 130th September, 2019

Place: Navi Mumbai

AT

# GENLINK PHARMA SOLUTIONS PRIVATE LIMITED

(Formerly known as GENLINK PHARMA INVESTMENTS PRIVATE LIMITED)

## Annexure 1

With reference to Regulation 52(4) Securities and Exchange Board of India (Listing Obligation and Disclosure requirements) Regulations, 2015 please find the disclosure as under for the financial year ended 31<sup>st</sup> March, 2019:

- 1. Credit rating** - The Company's NCDs have been rated as "ACUITE BB-" by **ACUITE RATINGS & RESEARCH LIMITED (erstwhile SMERA RATINGS LIMITED)**.
- 2. Asset cover available** - The asset cover ratio works out to more than one time on the basis of valuation of the equity shares offered as security for the NCDs.
- 3. Debt-equity ratio - 122.50 Times**
- 4. Previous due date for the payment of interest** - The Company has issued "Zero Coup" secured redeemable non-convertible debentures. Hence, no interest is required to be paid.
- 5. Repayment of principal of non-convertible debt securities** - The secured redeemable non-convertible debentures are redeemable in full on September 27, 2021.
- 6. Next due date for the payment of interest** - The Company has issued "Zero Coup" secured redeemable non-convertible debentures. Hence no due date is applicable.
- 7. Debt service coverage ratio - 4.17 Times**
- 8. Interest service coverage ratio - 8.92 Times**
- 9. Outstanding redeemable preference shares (quantity and value)** - The Company does not have any outstanding redeemable preference shares
- 10. Capital redemption reserve/debenture redemption reserve** - NIL
- 11. Net worth** - The net worth of the Company is Rs. 22,27,852/-
- 12. Net profit/loss after tax**  
Net loss after tax of the Company is Rs 48,97,780/-
- 13. Earnings per share**  
Earnings per share of the Company is Rs 489.78

Office: 1704, 17<sup>th</sup> Floor, Kesar Solitaire, Plot No. 5, Sector 19, Sanpada, Navi Mumbai - 400 705, India  
Ph: +91 22 6750 7000 Fax +91 22 6750 7070 Email [genlinkinfo@gmail.com](mailto:genlinkinfo@gmail.com) [www.genlinkpharma.com](http://www.genlinkpharma.com)

CIN: U74110 MH 2016 PTC 280765



# GENLINK PHARMA SOLUTIONS PRIVATE LIMITED

(Formerly known as GENLINK PHARMA INVESTMENTS PRIVATE LIMITED)

Date: 30/09/2019

To  
The Manager  
Listing Department  
BSE Limited  
Bombay Stock Exchange,  
P. J. Towers, Dalal Street,  
Mumbai-400001.

Subject: Declaration pursuant to Regulation 52(3)(a) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Scrip Code: Scrip code 956084 and ISIN INE988W07019

Dear Sir/Madam,

Pursuant to Regulation 52(3)(a) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended from time to time, I, Ganeshprasad Gupta, Company Secretary and Compliance Officer of Genlink Pharma Solutions Private Limited (Formerly Known as Genlink Pharma Investments Private Limited) (CIN: U74110MH2016PTC280765), having its Registered Office at Office No - 1704, 17<sup>th</sup> Floor, Kesar Solitaire, Plot No. 5, Sector 19, Sanpada, Navi Mumbai - 400705, Maharashtra, India, do hereby declare that, the Statutory Auditors of the Company, Shankarlal Jain & Associates LLP, Chartered Accountants (FRN 109901W/W100082) have issued an Audit Report with an unmodified opinion on the Audited Financial Results of the Company for the year ended March 31, 2019.

Kindly take this declaration on record.

Yours faithfully,

For Genlink Pharma Solutions Private Limited

  
G.A Gupta

Company Secretary & Compliance Officer

Membership no. ACS33925



# GENLINK PHARMA SOLUTIONS PRIVATE LIMITED

(Formerly known as GENLINK PHARMA INVESTMENTS PRIVATE LIMITED)

Date: 30/09/2019

To  
The Manager  
Listing Department  
BSE Limited  
Bombay Stock Exchange,  
P. J. Towers, Dalal Street,  
Mumbai-400001

Ref: Scrip code 956084 and ISIN INE988W07019


**Subject:** Statement of material deviation under Regulation 52(7) Securities and Exchange Board of India (Listing Obligation and Disclosure requirements) Regulations, 2015


Dear Sir/Madam,

With reference to Regulation 52(7) Securities and Exchange Board of India (Listing Obligation and Disclosure requirements) Regulations, 2015 we hereby state that for the year ended 31<sup>st</sup> March, 2019, there is no material deviation in the use of proceeds of Secured Redeemable Non-Convertible Debentures from the objects stated in the offer document.

Please take the above information on your records.

For Genlink Pharma Solutions Private Limited

  
G.A Gupta  
Company Secretary and Compliance Officer  
Membership no. ACS33925





# GENLINK PHARMA SOLUTIONS PRIVATE LIMITED

(Formerly known as GENLINK PHARMA INVESTMENTS PRIVATE LIMITED)


## DISCLOSURE UNDER REGULATION 54 OF SEBI (LODR), 2015


We hereby stated that the Company maintains as on 30<sup>th</sup> September, 2019 hundred percent asset cover sufficient to discharge the principal amount at all times for the non-convertible debt securities issued.

The details of extent and nature of security created and maintained with respect to its listed secured non-convertible redeemable debt securities are as follows:

1. 563,497 Equity shares of Enaltec Labs Pvt. Ltd. held by Genlink Pharma Solutions Private Limited.
2. 5,923 Equity shares of Enaltec Labs Pvt. Ltd. held by Mr. Anand Shah.
3. 5,923 Equity shares of Enaltec Labs Pvt. Ltd. held by Mr. Susheel Koul.

For Genlink Pharma Solutions Private Limited

  
G.A. Gupta  
Company Secretary & Compliance Officer  
Membership no. ACS33925





Date: October 04, 2019

To  
Mr. Anand Shah,  
Compliance Officer,  
Genlink Pharma Solutions Private Limited  
1704, 17th Floor, Kesar Solitaire,  
Plot No. 5, Sector 19,  
Sanpada, Navi Mumbai - 400 705,  
Maharashtra, India.

Ref: Scrip code 956084 and ISIN INE988W07019

Subject: Certificate of Debenture Trustee under Regulation 52(5) of SEBI (LODR), 2015 for the financial year ended 31<sup>st</sup> March, 2019.

In compliance with the requirement of Chapter V, Regulation 52(4) and 52(5) of the Securities and Exchange Board of India (Listing Obligation and Disclosure requirements) Regulations, 2015 for Secured Redeemable Non-Convertible Debentures it is certified as under:

We, Vistra ITCL (India) Limited, are acting as a Debenture Trustee for the debenture programme of Rated, Listed, Redeemable, Non-Convertible Debentures (NCDs) issue aggregating to Rs. 25 Crores of Genlink Pharma Solutions Private Limited (formerly known as Genlink Pharma Investments Private Limited), "the Company"


With reference to the above, we have received the following documents and noted its contents:

1. Audited financial results for the year ended 31<sup>st</sup> March 2019 along with Audit report for the year ended 31<sup>st</sup> March, 2019.
2. Disclosure pursuant to Regulation 52(4) of the Securities and Exchange Board of India (Listing Obligation and Disclosure Requirements) Regulations, 2015 for the financial year ended 31<sup>st</sup> March 2019.

This certificate has been signed and issued by us based on documents (mentioned above) submitted by you.

Thanking You.

Yours sincerely,  
For Vistra ITCL (India) Limited

  
Authorized signatory

Place: Mumbai